AB SCIEX has announced the launch of the second generation of the TripleTOF™ 5600 System. The new TripleTOF™ 5600+ System delivers novel innovation for biomolecule research with MS/MSALL with SWATH™ Acquisition and supports a higher level of selectivity when coupled with SelexION™ Technology.
The new system also comes with software that is capable of supporting 21 CFR Part 11 compliance, making TripleTOF™ technology more accessible for regulated labs in the pharmaceutical industry.
The TripleTOF 5600+ is on display at this week’s American Society of Mass Spectrometry (ASMS) conference in Vancouver.
The new TripleTOF™ 5600+ system represents an advance in accurate mass technology that combines high resolution with sensitivity and speed.
This system builds on the proven innovation of the original TripleTOF™ 5600, which was launched at ASMS in 2010, and is now the industry’s fastest, high sensitivity, high-resolution mass spectrometer for simultaneous high-performance qualitative and quantitative analysis.
A built-in capability to support SelexION™ Technology further adds versatility and breakthrough levels of selectivity.
SWATH™ Acquisition is a mass spectrometry-based technique that quantifies nearly all peptides and proteins in a sample from a single analysis.
By incorporating support for MS/MSALL with SWATH™ Acquisition on the TripleTOF™ 5600+ platform, researchers will be able to obtain more information about proteins, peptides and other biomolecules from a sample than ever before.
The TripleTOF™ 5600+ is the only platform in the industry that has the speed, sensitivity and dynamic range to enable SWATH™ Acquisition, which was developed through collaboration with leading proteomics researcher Ruedi Aebersold, Ph.D., based at ETH Zurich, and has already received positive feedback from the scientific community.
“The combination of the AB SCIEX TripleTOF™ 5600+ system and the recent development of SWATH acquisition has completely changed how I think about designing and implementing quantitative proteomics studies,” said Bradford W. Gibson, Ph.D., Professor & Director of Chemistry and Mass Spectrometry, Buck Institute for Research on Aging.
Gibson continued, “The high resolution and fast scanning capabilities of the TripleTOF have made it possible for the first time to acquire MS and MS/MS ion intensity data on essentially all peptides in a single run that can be mined both immediately and retrospectively. This is truly a revolutionary combination of instrumentation technologies and software innovation.”
AB SCIEX is extending the utility of TripleTOF™ technology for use in pharmaceutical laboratories, addressing a need for compliance to 21 CFR Part 11 for electronic records and signatures.
With software capable of supporting 21 CFR Part 11 compliance, the new TripleTOF solution opens up new possibilities for drug discovery labs to meet this regulatory requirement.
“The launch of the TripleTOF 5600+ System is exactly two years after the first TripleTOF instrument broke new ground in the mass spectrometry industry and changed the way scientists approach analyses of drugs, contaminants and proteins,” said Dave Hicks, Vice President of the Pharma & Academic Business at AB SCIEX.
Hicks continued, “Now, we are continuing the evolution of the TripleTOF platform with new functionality that directly addresses feedback from customers who want to push the limits in their quantitative and qualitative analyses.”
Compatibility with SelexION™ Technology is another new feature of the TripleTOF™ 5600+ system, developed in response to customer feedback.
SelexION™ Technology delivers a new dimension of selectivity by adding differential ion mobility to conventional mass spectrometry for both quantitative and qualitative analysis.
It significantly improves selectivity and performance for any application requiring the separation of isobaric species, isolation of challenging co-eluting contaminants and elimination of high background noise. This advancement reduces sample preparation requirements and improves overall data quality.